294 related articles for article (PubMed ID: 27700619)
21. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.
Kreiter S; Diken M; Selmi A; Diekmann J; Attig S; Hüsemann Y; Koslowski M; Huber C; Türeci Ö; Sahin U
Cancer Res; 2011 Oct; 71(19):6132-42. PubMed ID: 21816907
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
23. Melanoma vaccines: achievements and perspectives.
Brichard VG; Gérard C
Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
[TBL] [Abstract][Full Text] [Related]
24. Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
Sayour EJ; Mendez-Gomez HR; Mitchell DA
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249040
[TBL] [Abstract][Full Text] [Related]
25. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
26. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
27. Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kawashima M; Hiyama N; Murayama T; Kuwano H; Nitadori J; Anraku M; Sato M; Miyai M; Hosoi A; Matsushita H; Kikugawa S; Matoba R; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2016 Mar; 11(3):324-33. PubMed ID: 26752676
[TBL] [Abstract][Full Text] [Related]
28. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
29. Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine.
Parums DV
Med Sci Monit; 2021 May; 27():e933088. PubMed ID: 33994538
[TBL] [Abstract][Full Text] [Related]
30. Researchers push for personalized tumour vaccines.
Ledford H
Nature; 2016 Apr; 532(7600):425. PubMed ID: 27121818
[No Abstract] [Full Text] [Related]
31. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle-mediated tumor vaccines for personalized therapy: preparing tumor antigens
Li Q; Li J; Song S; Chen W; Shen X; Li S; Xing D
J Mater Chem B; 2021 Mar; 9(10):2352-2366. PubMed ID: 33659970
[TBL] [Abstract][Full Text] [Related]
33. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients.
Weide B; Pascolo S; Scheel B; Derhovanessian E; Pflugfelder A; Eigentler TK; Pawelec G; Hoerr I; Rammensee HG; Garbe C
J Immunother; 2009 Jun; 32(5):498-507. PubMed ID: 19609242
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for melanoma.
Komenaka I; Hoerig H; Kaufman HL
Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
[TBL] [Abstract][Full Text] [Related]
35. Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.
Zappasodi R; Merghoub T
Immunotherapy; 2015; 7(9):981-97. PubMed ID: 26310996
[TBL] [Abstract][Full Text] [Related]
36. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination.
Michiels A; Tuyaerts S; Bonehill A; Heirman C; Corthals J; Thielemans K
Methods Mol Biol; 2008; 423():155-63. PubMed ID: 18370196
[TBL] [Abstract][Full Text] [Related]
37. Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?
Dillman RO; Cornforth AN; Nistor G
Expert Opin Biol Ther; 2013 May; 13(5):643-56. PubMed ID: 23451922
[TBL] [Abstract][Full Text] [Related]
38. Current immunotherapeutic strategies in malignant melanoma.
Agostino NM; Ali A; Nair SG; Mosca PJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):945-73, xi. PubMed ID: 18022553
[TBL] [Abstract][Full Text] [Related]
39. Active immunotherapy with allogeneic tumor cell vaccines: present status.
Chan AD; Morton DL
Semin Oncol; 1998 Dec; 25(6):611-22. PubMed ID: 9865676
[TBL] [Abstract][Full Text] [Related]
40. Melanoma vaccines: developments over the past 10 years.
Klein O; Schmidt C; Knights A; Davis ID; Chen W; Cebon J
Expert Rev Vaccines; 2011 Jun; 10(6):853-73. PubMed ID: 21692705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
